| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1369787 | Bioorganic & Medicinal Chemistry Letters | 2012 | 4 Pages |
NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several compounds that were synthesized and evaluated in a HCV genotype 1b replicon. The straight triphenyl linked compound 11a showed similar anti-HCV activity to the clinical compound BMS-790052 and a superior cytotoxicity profile in three different cell lines, with an EC50 value of 26 pM and a therapeutic index of over four million in an HCV replicon assay. This triphenyl analog warrants further preclinical evaluation as an anti-HCV agent.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
